intralymphatic insulin immunotherapy

Intralymphatic insulin immunotherapy (ILIT) is an antigen-specific tolerance induction strategy being investigated for the treatment of recent-onset Type 1 diabetes. The approach involves the direct injection of insulin (the autoantigen) into a lymph node, typically the inguinal lymph node, to promote immune tolerance and the expansion of insulin-specific regulatory T cells (Tregs). This method aims to protect remaining pancreatic beta cells from autoimmune destruction by teaching the immune system to tolerate insulin rather than attack it. In the MATIN-2 clinical trial framework, ILIT is evaluated as part of a sequential regimen following teplizumab (an anti-CD3 antibody) and is administered alongside low-dose interleukin-2 (IL-2) to stabilize and maintain the tolerogenic environment.

Other names

intralymphatic insulinintralymphatic immunotherapy with insulin